Should You Add Marijuana Stocks to Your Portfolio?
Investors should keep close watch on the developments in marijuana legalization in order to capitalize on the growth of this market.
As some US states have migrated toward the legalization of marijuana, most have failed to appreciate the potential economic and societal benefits that this legislature would provide. Over 500 economists signed a letter to governmental bodies citing the likely benefits of marijuana legalization.
From an economic standpoint, marijuana legalization would save $7.7 billion per year in funds spent on prohibition enforcement, and it would also generate about $6 billion in tax revenue each year. Not only does the legalization of marijuana make sense quantitatively, but the new industry that has emerged could create many new jobs and open up a whole new market for consumers to spend and boost the economy.
While opposition to its legalization argue that it would encourage moral decay throughout society, it has been argued that marijuana-related crimes would decrease and subsequently, drug-related arrests would decline as well.
Currently, there are 15 states that have enacted legislature legalizing marijuana. This is only the beginning to what may become a new and profitable industry. Consequently, investors have an interesting opportunity to consider.
Much like the technology bubble in which there was an influx of tech-related stocks that eventually crashed and burned, investors must use due diligence to choose marijuana-related stocks with the best chance of surviving and earning competitive returns. Consider the stock, Medical Marijuana. Medical Marijuana helped other organizations maintain rules compliance as well as manage legal and tax obligations. However, this company now trades over the country at $0.04 down from a high of $0.64 in mid-2009. This is a great example of how quickly companies can fail in new markets.
To hedge risk in the marijuana market, investors might consider investing in a company that's products and services are further-reaching than just the marijuana market. For example, consider Valeant Pharmaceuticals International (VRX). This company struggled in 2010 with much higher operating costs than 2009 and profit was unable to keep pace resulting in a negative net income for the year. Valeant develops, manufactures, and markets many pharmaceutical products in neurology and dermatology. However, it also makes Nabilone, a form of synthetic THC, which may be the key in the emerging market of marijuana. Like many pharmaceuticals, Valeant may be a risky bet as it had a -17.63 profit margin in 2010.
While there are few marijuana-related stocks that are both actively exchange-traded and possess quality financials, it may be a good idea for investors to keep close watch on the legal developments in order to capitalize on the growth of this market.
Below, find some more great ETF and market content from Benzinga:
Four ETFs for St. Patrick’s Day
By The ETF Professor
How to Trade on Nuclear Power Concerns
By Daniel James Hayden IV
Who Saw It Coming? Wynne Godley
By L. Randall Wray
Lasting through April 15, 100% of the donations made to The Ruby Peck Foundation for Children's Education will be channeled to the children of Japan as they attempt to find their footing following this natural disaster; and to kick off this drive, we'll pledge $5000 to get it started. Please do what you can, as it will add up, and thanks.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.
Copyright 2011 Minyanville Media, Inc. All Rights Reserved.